A detailed history of Wells Fargo & Company transactions in Calliditas Therapeutics Ab stock. As of the latest transaction made, Wells Fargo & Company holds 1,500 shares of CALT stock, worth $60,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,500
Previous 3,760 60.11%
Holding current value
$60,000
Previous $78,000 25.64%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$17.65 - $41.41 $39,889 - $93,586
-2,260 Reduced 60.11%
1,500 $58,000
Q1 2024

May 10, 2024

BUY
$20.04 - $25.66 $45,290 - $57,991
2,260 Added 150.67%
3,760 $78,000
Q4 2023

Feb 09, 2024

BUY
$15.79 - $28.99 $23,685 - $43,485
1,500 New
1,500 $38,000
Q2 2022

Aug 12, 2022

SELL
$12.85 - $20.36 $8,082 - $12,806
-629 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$15.14 - $25.55 $5,223 - $8,814
345 Added 121.48%
629 $12,000
Q2 2021

Aug 16, 2021

BUY
$26.02 - $31.17 $7,389 - $8,852
284 New
284 $8,000

Others Institutions Holding CALT

About Calliditas Therapeutics AB


  • Ticker CALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,624,800
  • Market Cap $1.06B
  • Description
  • Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...
More about CALT
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.